Medicare Coding Change For Biosimilars Could Save $65bn, Firms Say
Executive Summary
Biopharma manufacturers, payers and other stakeholders strongly support changing an Obama-era policy for reimbursing biosimilars under Medicare Part B in comments to the Centers for Medicare and Medicaid Services.
You may also be interested in...
Building A Biosimilars Market: Lessons From The US Launches
Provider trust in the biosimilar is as important as price in the nascent market and biosimilars need more commercialization support than innovators to obtain it, executives from AmerisourceBergen advise.
Building A Biosimilars Market: Lessons From The US Launches
Provider trust in the biosimilar is as important as price in the nascent market and biosimilars need more commercialization support than innovators to obtain it, executives from AmerisourceBergen advise.
Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'
Decision reflects Trump Administration's willingness to reconsider past efforts at cost control to address biopharma industry's concerns.